-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Metastatic Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Metastatic Melanoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Metastatic Melanoma Drug Details: Lenvatinib mesylate (Lenvima...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in High-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in High-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in High-Grade Glioma Drug Details: Lenvatinib mesylate (Lenvima...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Lenvatinib Mesylate in Merkel Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Lenvatinib Mesylate in Merkel Cell Carcinoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Lenvatinib Mesylate in Merkel Cell Carcinoma Drug Details: Lenvatinib...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – THN-391 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - THN-391 in Alzheimer's Disease report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. THN-391 in Alzheimer's Disease Drug Details: THN-391 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AT-101 in Follicular Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AT-101 in Follicular Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AT-101 in Follicular Lymphoma Drug Details: AT-101 is under development for...
-
Product Insights
NewNet Present Value Model: 89bio Inc’s Pegozafermin
Empower your strategies with our Net Present Value Model: 89bio Inc's Pegozafermin report and make more profitable business decisions. Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LNS-8801 in Metastatic Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LNS-8801 in Metastatic Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LNS-8801 in Metastatic Pancreatic Cancer Drug Details: LNS-8801 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – RLY-2608 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - RLY-2608 in Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer (HER2- Breast Cancer) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. RLY-2608...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seralutinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seralutinib in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seralutinib in Pulmonary Arterial Hypertension Drug Details: Seralutinib is under...